

Katelyn W Sylvester

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2016116/publications.pdf>

Version: 2024-02-01

45
papers

545
citations

759233

12
h-index

677142

22
g-index

45
all docs

45
docs citations

45
times ranked

1052
citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluation of Dose-Reduced Direct Oral Anticoagulant Therapy. American Journal of Medicine, 2016, 129, 1198-1204.	1.5	121
2	VTE in ICU Patients With COVID-19. Chest, 2020, 158, 2130-2135.	0.8	76
3	Andexanet Alfa for Urgent Reversal of Apixaban Before Aortic Surgery Requiring Cardiopulmonary Bypass: A Case Report. A&A Practice, 2019, 13, 271-273.	0.4	30
4	Expanding anticoagulation management services to include direct oral anticoagulants. Journal of Thrombosis and Thrombolysis, 2018, 45, 274-280.	2.1	26
5	Andexanet alfa—The first 150 days. American Journal of Hematology, 2019, 94, E21-E24.	4.1	26
6	Cerebrovascular Accidents During Mechanical Circulatory Support. Stroke, 2018, 49, 1197-1203.	2.0	21
7	Evaluation of Antifactor-Xa Heparin Assay and Activated Partial Thromboplastin Time Values in Patients on Therapeutic Continuous Infusion Unfractionated Heparin Therapy. Clinical and Applied Thrombosis/Hemostasis, 2019, 25, 107602961987603.	1.7	20
8	Evaluation of oral factor Xa inhibitor—associated extracranial bleeding reversal with andexanet alfa. Journal of Thrombosis and Haemostasis, 2020, 18, 2532-2541.	3.8	20
9	Andexanet Alfa (Andexxa) Formulary Review. Critical Pathways in Cardiology, 2019, 18, 66-71.	0.5	17
10	Four factor prothrombin complex concentrate for warfarin reversal in patients with left ventricular assist devices. Journal of Thrombosis and Thrombolysis, 2018, 46, 180-185.	2.1	16
11	Idarucizumab for urgent reversal of dabigatran for heart transplant: A case report. American Journal of Hematology, 2017, 92, E34-E35.	4.1	15
12	Description and Evaluation of the Implementation of a Weight-Based, Nurse-Driven Heparin Nomogram in a Tertiary Academic Medical Center. Clinical and Applied Thrombosis/Hemostasis, 2018, 24, 248-253.	1.7	15
13	Esomeprazole and aspirin fixed combination for the prevention of cardiovascular events. Vascular Health and Risk Management, 2013, 9, 245.	2.3	10
14	Time in the Therapeutic Range for Assessing Anticoagulation Quality in Patients Receiving Continuous Unfractionated Heparin. Clinical and Applied Thrombosis/Hemostasis, 2018, 24, 178S-181S.	1.7	10
15	Development of Multidisciplinary Anticoagulation Management Guidelines for Patients Receiving Durable Mechanical Circulatory Support. Clinical and Applied Thrombosis/Hemostasis, 2019, 25, 107602961983736.	1.7	10
16	Optimization of DOAC management services in a centralized anticoagulation clinic. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12696.	2.3	10
17	Coordinating emergent procedures after andexanet alfa. American Journal of Hematology, 2019, 94, E278-E282.	4.1	9
18	Biosimilars: An Emerging Category of Biologic Drugs for Emergency Medicine Practitioners. Current Emergency and Hospital Medicine Reports, 2013, 1, 226-235.	1.5	8

#	ARTICLE	IF	CITATIONS
19	Direct Thrombin Inhibitor for LVAD Thrombosis: A Closer Look. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017, 23, 405-409.	1.7	8
20	Intermediate versus standard dose heparin prophylaxis in COVID-19 ICU patients: A propensity score-matched analysis. <i>Thrombosis Research</i> , 2021, 203, 57-60.	1.7	8
21	Impact of an Immunoglobulin G-Specific Enzyme-Linked Immunosorbent Assay on the Management of Heparin-Induced Thrombocytopenia. <i>Pharmacotherapy</i> , 2013, 33, 1191-1198.	2.6	7
22	Comparison of an IgG-Specific Enzyme-Linked Immunosorbent Assay Cutoff of 0.4 Versus 0.8 and 1.0 Optical Density Units for Heparin-Induced Thrombocytopenia. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017, 23, 282-286.	1.7	7
23	Development of a Predictive Nomogram for the Change in PT/INR Upon Discontinuation of Bivalirudin as a Bridge to Warfarin. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017, 23, 487-493.	1.7	5
24	Evaluation of Compliance with a Weight-based Nurse-driven Heparin Nomogram in a Tertiary Academic Medical Center. <i>Critical Pathways in Cardiology</i> , 2018, 17, 83-87.	0.5	5
25	Derivation and Validation of Age- and Body Mass Index-Adjusted Weight-Based Unfractionated Heparin Dosing. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961983348.	1.7	4
26	Heparin-Induced Thrombocytopenia and Cardiac Surgery: A Role for Hematologists in Critical Care Units. <i>Blood</i> , 2011, 118, 2062-2062.	1.4	4
27	Prothrombin Complex Concentrate for Non-Bleeding Urgent Warfarin Reversal in Ventricular Assist Device Patients Undergoing Heart Transplantation. <i>Current Emergency and Hospital Medicine Reports</i> , 2016, 4, 93-97.	1.5	3
28	Prospective evaluation of a bivalirudin to warfarin transition nomogram. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 43, 498-504.	2.1	3
29	Warfarin management in the setting of FVII deficiency and mechanical circulatory support. <i>Vascular Medicine</i> , 2017, 22, 345-346.	1.5	3
30	Utilization of an Integrated Electronic Health Record in the Emergency Department to Increase Prospective Medication Order Review by Pharmacists. <i>Journal of Pharmacy Practice</i> , 2018, 31, 636-641.	1.0	3
31	Evaluation and optimization of prescribed concomitant antiplatelet and anticoagulation therapy centrally managed by an anticoagulation management service. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 405-412.	2.1	3
32	Management of therapeutic unfractionated heparin in COVID-19 patients: A retrospective cohort study. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12521.	2.3	3
33	Heparin-induced thrombocytopenia in end-stage renal disease: Reliability of the PF4-heparin ELISA. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12573.	2.3	3
34	To aPTT or not to aPTT: Evaluating the optimal monitoring strategy for unfractionated heparin. <i>Thrombosis Research</i> , 2022, 218, 199-200.	1.7	3
35	Women's representation in venous thromboembolism randomized trials and registries: The illustrative example of direct oral anticoagulants for acute treatment. <i>Contemporary Clinical Trials</i> , 2022, 115, 106714.	1.8	3
36	Pharmacy Response to the Boston Marathon Bombings at a Tertiary Academic Medical Center. <i>Annals of Pharmacotherapy</i> , 2014, 48, 1082-1085.	1.9	2

#	ARTICLE	IF	CITATIONS
37	Betrixaban in the prevention of venous thromboembolism in medically ill patients. <i>Future Cardiology</i> , 2018, 14, 455-470.	1.2	2
38	Overcoming barriers to integrating direct oral anticoagulants into existing anticoagulation management services. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2019, 3, 136-137.	2.3	2
39	Prothrombin complex concentrate for factor VII replacement in a patient undergoing left ventricular assist device implantation with factor VII deficiency. <i>American Journal of Hematology</i> , 2015, 90, E185.	4.1	1
40	Development of an Institutional Perioperative Management Guideline for Oral Anticoagulants. <i>Critical Pathways in Cardiology</i> , 2020, 19, 178-186.	0.5	1
41	Atrial Fibrillation Patients on Warfarin and Their Transition to Direct Oral Anticoagulants. <i>Critical Pathways in Cardiology</i> , 2021, 20, 103-107.	0.5	1
42	A Review of Direct-acting Oral Anticoagulants and Their Use in Solid Organ Transplantation. <i>Transplantation</i> , 2022, 106, 2143-2154.	1.0	1
43	Thromboprophylaxis Strategies in Acute Medically Ill Patients. <i>Current Emergency and Hospital Medicine Reports</i> , 2019, 7, 118-126.	1.5	0
44	Reasons for new patient warfarin referrals to an anticoagulant management service in 2019: a single institution experience. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 52, 158-160.	2.1	0
45	Extended duration venous thromboembolism prophylaxis with betrixaban for patients re-admitted with venous thromboembolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 52, 22-29.	2.1	0